Crizanlizumab
Crizanlizumab-tmca is a monoclonal antibody designed to reduce the frequency of painful crises in patients with sickle cell disease aged 16 years and older. It works by binding to P-selectin, a protein on the surface of blood vessel lining cells and platelets, preventing red blood cells from sticking together and blocking blood flow. This medication is given as an intravenous infusion.
Crizanlizumab-tmca is a monoclonal antibody infusion used to prevent painful crises in adults and adolescents with sickle cell disease.
Key facts at a glance
- RxNorm
- 2262421
- Generic
- Crizanlizumab-Tmca
- Class
- pin-variant
- Brands
- Adakveo
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Crizanlizumab-tmca is indicated to reduce the frequency of vaso-occlusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease. It may be used as monotherapy or in combination with hydroxyurea.
This medication is a monoclonal antibody that binds to P-selectin, a cell adhesion molecule expressed on activated endothelial cells and platelets. By blocking P-selectin, it prevents interactions between red blood cells, white blood cells, platelets, and blood vessel walls that lead to vaso-occlusion and painful crises.
Crizanlizumab-tmca is administered as an intravenous infusion over 30 minutes every 4 weeks. Common side effects may include infusion-related reactions, joint pain, back pain, and abdominal pain. Patients should be monitored during infusion for potential reactions. This medication does not cure sickle cell disease and should be used as part of a comprehensive care plan.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy